These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39044437)

  • 21. Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents.
    Hu X; Gao X; Gao G; Wang Y; Cao H; Li D; Hua H
    Bioorg Med Chem Lett; 2021 May; 40():127952. PubMed ID: 33744443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
    Chen L; Long C; Nguyen J; Kumar D; Lee J
    Bioorg Med Chem Lett; 2018 Feb; 28(3):420-424. PubMed ID: 29287960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
    Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
    Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cycloplatinated (II) Complex Based on Isoquinoline Alkaloid Elicits Ferritinophagy-Dependent Ferroptosis in Triple-Negative Breast Cancer Cells.
    Wang FY; Yang LM; Wang SS; Lu H; Wang XS; Lu Y; Ni WX; Liang H; Huang KB
    J Med Chem; 2024 Apr; 67(8):6738-6748. PubMed ID: 38526421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysophosphatidic Acid Receptor 1 (LPA
    Liu W; Mousa AAK; Hopkins AM; Wu YF; Thu KL; Campbell M; Lees SJ; Ramachandran R; Hou J
    ChemMedChem; 2024 Aug; 19(16):e202400013. PubMed ID: 38648251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
    Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
    Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferroptosis as a promising targeted therapy for triple negative breast cancer.
    Mokhtarpour K; Razi S; Rezaei N
    Breast Cancer Res Treat; 2024 Oct; 207(3):497-513. PubMed ID: 38874688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
    Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
    J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis.
    Yang X; Liang B; Zhang L; Zhang M; Ma M; Qing L; Yang H; Huang G; Zhao J
    Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38847277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
    Shen LW; Jiang XX; Li ZQ; Li J; Wang M; Jia GF; Ding X; Lei L; Gong QH; Gao N
    Acta Pharmacol Sin; 2022 Jan; 43(1):177-193. PubMed ID: 34294886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer.
    Zajec Ž; Dernovšek J; Cingl J; Ogris I; Gedgaudas M; Zubrienė A; Mitrović A; Golič Grdadolnik S; Gobec M; Tomašič T
    J Med Chem; 2024 Aug; 67(15):12984-13018. PubMed ID: 39042910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.